{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T14:01:48Z","timestamp":1780581708718,"version":"3.54.1"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI17CIII\/00003"],"award-info":[{"award-number":["PI17CIII\/00003"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI17\/00657"],"award-info":[{"award-number":["PI17\/00657"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI17\/00903"],"award-info":[{"award-number":["PI17\/00903"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CP17CIII\/00007"],"award-info":[{"award-number":["CP17CIII\/00007"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI18CIII\/00028"],"award-info":[{"award-number":["PI18CIII\/00028"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["RD16CIII\/0002\/0002"],"award-info":[{"award-number":["RD16CIII\/0002\/0002"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["RD16\/0025\/0017"],"award-info":[{"award-number":["RD16\/0025\/0017"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["RD16\/0025\/0018"],"award-info":[{"award-number":["RD16\/0025\/0018"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI20\/00507"],"award-info":[{"award-number":["PI20\/00507"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI20CIII\/00004"],"award-info":[{"award-number":["PI20CIII\/00004"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI20\/00474"],"award-info":[{"award-number":["PI20\/00474"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Eradication of hepatitis C virus (HCV) promotes an improvement in liver disease and the deactivation of the immune system. Here, we aimed to evaluate the changes in liver disease scores and plasma biomarkers following HCV clearance with direct-acting antivirals (DAAs) in HIV-infected patients with advanced HCV-related cirrhosis.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> We performed an observational study of 50 patients with advanced cirrhosis who received DAAs therapy. Variables were assessed at baseline and 48 weeks after HCV treatment completion. Epidemiological and clinical data were collected through an online form. Liver stiffness measurement (LSM), hepatic venous pressure gradient (HVPG), and Child-Pugh-Turcotte (CTP) were evaluated by physicians. Plasma biomarkers were measured by multiplex immunoassay.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> We found significant decreases in severity scores of liver disease [LSM (<jats:italic>q<\/jats:italic>-value &amp;lt; 0.001), HVPG (<jats:italic>q<\/jats:italic>-value = 0.011), and CTP (<jats:italic>q<\/jats:italic>-value = 0.045)] and plasma biomarkers [LBP (<jats:italic>q<\/jats:italic>-value &amp;lt; 0.001), IP-10 (<jats:italic>q<\/jats:italic>-value &amp;lt; 0.001), IL-8 (<jats:italic>q<\/jats:italic>-value &amp;lt; 0.001), IL-18 (<jats:italic>q<\/jats:italic>-value &amp;lt; 0.001), IL-1RA (<jats:italic>q<\/jats:italic>-value = 0.013), OPG (<jats:italic>q<\/jats:italic>-value &amp;lt; 0.001), sVCAM-1 (<jats:italic>q<\/jats:italic>-value &amp;lt; 0.001), sICAM-1 (<jats:italic>q<\/jats:italic>-value &amp;lt; 0.001), PAI-1 (<jats:italic>q<\/jats:italic>-value = 0.001), and VEGF-A (<jats:italic>q<\/jats:italic>-value = 0.006)]. We also found a significant direct association between the change in LSM values and the change in values of LBP (<jats:italic>q<\/jats:italic>-value &amp;lt; 0.001), IP-10 (<jats:italic>q<\/jats:italic>-value &amp;lt; 0.001), MCP-1 (<jats:italic>q<\/jats:italic>-value = 0.008), IL-8 (<jats:italic>q<\/jats:italic>-value &amp;lt; 0.001), IL-18 (<jats:italic>q<\/jats:italic>-value &amp;lt; 0.001), OPG (<jats:italic>q<\/jats:italic>-value = 0.004), sVCAM-1 (<jats:italic>q<\/jats:italic>-value &amp;lt; 0.001), sICAM-1 (<jats:italic>q<\/jats:italic>-value &amp;lt; 0.001), and PAI-1 (<jats:italic>q<\/jats:italic>-value = 0.002). For CTP values, we found significant positive associations with IP-10 (<jats:italic>q<\/jats:italic>-value = 0.010), IL-6 (<jats:italic>q<\/jats:italic>-value = 0.010), IL-1RA (<jats:italic>q<\/jats:italic>-value = 0.033), and sICAM-1 (<jats:italic>q<\/jats:italic>-value = 0.010).<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> The HCV eradication with all-oral DAAs in HIV\/HCV-coinfected patients with advanced cirrhosis promoted an improvement in the severity of advanced cirrhosis and plasma biomarkers (inflammation, coagulopathy, and angiogenesis). The decrease in plasma biomarkers was mainly related to the reduction in LSM values.<\/jats:p>","DOI":"10.3389\/fmed.2021.615342","type":"journal-article","created":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T05:07:47Z","timestamp":1612156067000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["Successful HCV Therapy Reduces Liver Disease Severity and Inflammation Biomarkers in HIV\/HCV-Coinfected Patients With Advanced Cirrhosis: A Cohort Study"],"prefix":"10.3389","volume":"8","author":[{"given":"Luz Maria","family":"Medrano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Berenguer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Salg\u00fcero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Gonz\u00e1lez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"D\u00edez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00edctor","family":"Honta\u00f1\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Garcia-Broncano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Iba\u00f1ez-Samaniego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 M.","family":"Bell\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Angeles","family":"Jim\u00e9nez-Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvador","family":"Resino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,2,1]]},"reference":[{"key":"B1","first-page":"3","article-title":"Hepatitis C Virus, Inflammation, and Cellular Aging: Turning Back Time","volume":"25","author":"Naggie","year":"2017","journal-title":"Top Antivir Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/nri.2016.69","article-title":"Immune responses and immunopathology in acute and chronic viral hepatitis","volume":"16","author":"Shin","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/j.jhep.2014.08.010","article-title":"Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance","volume":"61","author":"Albillos","year":"2014","journal-title":"J Hepatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/nrgastro.2016.176","article-title":"Global epidemiology and burden of HCV infection and HCV-related disease","volume":"14","author":"Thrift","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1177\/2050640619840149","article-title":"Hepatitis C virus therapy in advanced liver disease: outcomes and challenges","volume":"7","author":"Ekpanyapong","year":"2019","journal-title":"United European Gastroenterol J"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1111\/jgh.14707","article-title":"Effectiveness of direct-acting agents for hepatitis C and liver stiffness changing after sustained virological response","volume":"34","author":"Fernandes","year":"2019","journal-title":"J Gastroenterol Hepatol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/jvh.12990","article-title":"Similar recovery of liver function after response to all-oral HCV therapy in patients with cirrhosis with and without HIV coinfection","volume":"26","author":"Macias","year":"2019","journal-title":"J Viral Hepat"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e0214323","DOI":"10.1371\/journal.pone.0214323","article-title":"The change in liver stiffness, controlled attenuation parameter and fibrosis-4 index for chronic hepatitis C patients with direct-acting antivirals","volume":"14","author":"Lee","year":"2019","journal-title":"PLoS ONE"},{"key":"B9","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1111\/jvh.12706","article-title":"Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension","volume":"24","author":"Afdhal","year":"2017","journal-title":"J Viral Hepat"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1053\/j.gastro.2017.07.016","article-title":"Effects of all-oral anti-viral therapy on HVPG and systemic hemodynamics in patients with hepatitis C virus-associated cirrhosis","volume":"153","author":"Lens","year":"2017","journal-title":"Gastroenterology"},{"key":"B11","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.jhep.2016.05.027","article-title":"Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension","volume":"65","author":"Mandorfer","year":"2016","journal-title":"J Hepatol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s12072-018-9914-6","article-title":"Treatment with direct-acting antivirals improves the clinical outcome in patients with HCV-related decompensated cirrhosis: results from an Italian real-life cohort (Liver Network Activity-LINA cohort)","volume":"13","author":"Gentile","year":"2019","journal-title":"Hepatol Int"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1053\/j.gastro.2018.03.022","article-title":"Baseline factors associated with improvements in decompensated cirrhosis after direct-acting antiviral therapy for hepatitis C virus infection","volume":"154","author":"El-Sherif","year":"2018","journal-title":"Gastroenterology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1111\/apt.14404","article-title":"Sofosbuvir and daclatasvir therapy in patients with hepatitis C-related advanced decompensated liver disease (MELD > \/ = 15)","volume":"47","author":"McCaughan","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1111\/apt.15004","article-title":"Influence of hepatitis C virus eradication with direct-acting antivirals on the gut microbiota in patients with cirrhosis","volume":"48","author":"Ponziani","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e0170028","DOI":"10.1371\/journal.pone.0170028","article-title":"High serum lipopolysaccharide-binding protein level in chronic hepatitis C viral infection is reduced by anti-viral treatments","volume":"12","author":"Nien","year":"2017","journal-title":"PLoS ONE"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1111\/apt.14994","article-title":"Microbial translocation and T cell activation are modified by direct-acting antiviral therapy in HCV-infected patients","volume":"48","author":"Lattanzi","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e0179400","DOI":"10.1371\/journal.pone.0179400","article-title":"Changes in inflammatory biomarkers in HCV-infected patients undergoing direct acting antiviral-containing regimens with or without interferon","volume":"12","author":"Mascia","year":"2017","journal-title":"PLoS ONE"},{"key":"B19","doi-asserted-by":"publisher","first-page":"8578051","DOI":"10.1155\/2018\/8578051","article-title":"Restoring inflammatory mediator balance after Sofosbuvir-induced viral clearance in patients with chronic hepatitis C","volume":"2018","author":"Saraiva","year":"2018","journal-title":"Mediators Inflamm"},{"key":"B20","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/jvh.13204","article-title":"Time-dependent improvement of liver inflammation, fibrosis, and metabolic liver function after successful direct-acting antiviral therapy of chronic hepatitis C","volume":"27","author":"Laursen","year":"2019","journal-title":"J Viral Hepat"},{"key":"B21","doi-asserted-by":"publisher","first-page":"369","DOI":"10.7326\/M13-1829","article-title":"Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study","volume":"160","author":"Lo Re","year":"2014","journal-title":"Ann Intern Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/nrgastro.2014.17","article-title":"HCV and HIV co-infection: mechanisms and management","volume":"11","author":"Chen","year":"2014","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1007\/s12072-018-9896-4","article-title":"A changing paradigm: management and treatment of the HCV\/HIV-co-infected patient","volume":"12","author":"Abutaleb","year":"2018","journal-title":"Hepatol Int"},{"key":"B24","doi-asserted-by":"publisher","first-page":"S44","DOI":"10.1093\/infdis\/jiw275","article-title":"Immunologic biomarkers, morbidity, and mortality in treated HIV infection","volume":"214","author":"Hunt","year":"2016","journal-title":"J Infect Dis"},{"key":"B25","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1002\/hep.29642","article-title":"Hepatitis C and human immunodeficiency virus coinfection in the era of direct-acting antiviral agents: no longer a difficult-to-treat population","volume":"67","author":"Sikavi","year":"2018","journal-title":"Hepatology"},{"key":"B26","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/liv.13626","article-title":"Treatment of hepatitis C: the use of the new pangenotypic direct-acting antivirals in \u201cspecial populations\u201d","volume":"38","author":"Pol","year":"2018","journal-title":"Liver Int"},{"key":"B27","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1093\/cid\/cis500","article-title":"Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and Hepatitis C virus","volume":"55","author":"Berenguer","year":"2012","journal-title":"Clin Infect Dis"},{"key":"B28","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/hep.29071","article-title":"Eradication of hepatitis C virus and non-liver-related non-acquired immune deficiency syndrome-related events in human immunodeficiency virus\/hepatitis C virus coinfection","volume":"66","author":"Berenguer","year":"2017","journal-title":"Hepatology"},{"key":"B29","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1111\/jvh.12836","article-title":"IFN-free therapy is associated with restoration of type I IFN response in HIV-1 patients with acute HCV infection who achieve SVR","volume":"25","author":"Carlton-Smith","year":"2018","journal-title":"J Viral Hepat"},{"key":"B30","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1093\/infdis\/jiy136","article-title":"Eradication of hepatitis C virus (HCV) reduces immune activation, microbial translocation, and the HIV DNA level in HIV\/HCV-coinfected patients","volume":"218","author":"Lopez-Cortes","year":"2018","journal-title":"J Infect Dis"},{"key":"B31","doi-asserted-by":"publisher","first-page":"149","DOI":"10.20411\/pai.v3i1.242","article-title":"Soluble markers of immune activation differentially normalize and selectively associate with improvement in AST, ALT, albumin, and transient elastography during IFN-free HCV therapy","volume":"3","author":"Kostadinova","year":"2018","journal-title":"Pathog Immun"},{"key":"B32","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s00430-018-0538-1","article-title":"Soluble CD163 and soluble CD14 plasma levels but not cellular HIV-DNA decrease during successful interferon-free anti-HCV therapy in HIV-1-HCV co-infected patients on effective combined anti-HIV treatment","volume":"207","author":"Parisi","year":"2018","journal-title":"Med Microbiol Immunol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.clinre.2017.11.006","article-title":"Direct-acting antiviral therapy enhances total CD4+ and CD8+ T-cells responses, but does not alter T-cells activation among HCV mono-infected, and HCV\/HIV-1 co-infected patients","volume":"42","author":"Najafi Fard","year":"2018","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"5297","DOI":"10.3748\/wjg.v24.i47.5297","article-title":"Hepatitis C: From inflammatory pathogenesis to anti-inflammatory\/hepatoprotective therapy","volume":"24","author":"Li","year":"2018","journal-title":"World J Gastroenterol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1097\/QAD.0000000000001787","article-title":"Elevated liver stiffness is linked to increased biomarkers of inflammation and immune activation in HIV\/hepatitis C virus-coinfected patients","volume":"32","author":"Medrano","year":"2018","journal-title":"AIDS"},{"key":"B36","doi-asserted-by":"publisher","first-page":"487","DOI":"10.3109\/00365521.2012.711848","article-title":"Prognostic value of hepatic venous pressure gradient in patients with compensated chronic hepatitis C-related cirrhosis","volume":"48","author":"Rincon","year":"2013","journal-title":"Scand J Gastroenterol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"26996","DOI":"10.1038\/srep26996","article-title":"The statistical value of raw fluorescence signal in Luminex xMAP based multiplex immunoassays","volume":"6","author":"Breen","year":"2016","journal-title":"Sci Rep"},{"key":"B38","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1089\/jir.2012.0048","article-title":"Cytokine levels and histopathology in chronic hepatitis B and chronic hepatitis C","volume":"32","author":"Akcam","year":"2012","journal-title":"J Interferon Cytokine Res"},{"key":"B39","doi-asserted-by":"publisher","first-page":"4427","DOI":"10.3748\/wjg.v22.i18.4427","article-title":"Thrombin activation and liver inflammation in advanced hepatitis C virus infection","volume":"22","author":"Gonzalez-Reimers","year":"2016","journal-title":"World J Gastroenterol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1097\/COH.0b013e32835c7134","article-title":"Soluble biomarkers of HIV transmission, disease progression and comorbidities","volume":"8","author":"Leeansyah","year":"2013","journal-title":"Curr Opin HIV AIDS"},{"key":"B41","first-page":"121","article-title":"Advanced liver disease: what every hepatitis C virus treater should know","volume":"19","author":"Sherman","year":"2011","journal-title":"Top Antivir Med"},{"key":"B42","doi-asserted-by":"publisher","first-page":"10384","DOI":"10.1038\/s41598-020-67159-3","article-title":"Plasma IP-10 and IL-6 are linked to Child-Pugh B cirrhosis in patients with advanced HCV-related cirrhosis: a cross-sectional study","volume":"10","author":"Salguero","year":"2020","journal-title":"Sci Rep"},{"key":"B43","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/apt.13844","article-title":"Interferon-free regimens improve portal hypertension and histological necroinflammation in HIV\/HCV patients with advanced liver disease","volume":"45","author":"Schwabl","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"B44","doi-asserted-by":"publisher","first-page":"2850","DOI":"10.1093\/jac\/dkx223","article-title":"Efficacy and safety of direct antiviral agents in a cohort of cirrhotic HCV\/HIV-coinfected patients","volume":"72","author":"Navarro","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"B45","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1097\/QAD.0000000000001966","article-title":"Regression of liver fibrosis after curing chronic hepatitis C with oral antivirals in patients with and without HIV coinfection","volume":"32","author":"Lledo","year":"2018","journal-title":"Aids"},{"key":"B46","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/nrgastro.2017.38","article-title":"Mechanisms of hepatic stellate cell activation","volume":"14","author":"Tsuchida","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1158\/1078-0432.CCR-18-1254","article-title":"The role of angiogenesis in hepatocellular carcinoma","volume":"25","author":"Morse","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1002\/hep.27343","article-title":"Molecular pathophysiology of portal hypertension","volume":"61","author":"Fernandez","year":"2015","journal-title":"Hepatology"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1002\/hep.29911","article-title":"Liver angiopoietin-2 is a key predictor of de novo or recurrent hepatocellular cancer after hepatitis C virus direct-acting antivirals","volume":"68","author":"Faillaci","year":"2018","journal-title":"Hepatology"},{"key":"B50","doi-asserted-by":"publisher","first-page":"e0167934","DOI":"10.1371\/journal.pone.0167934","article-title":"DAAs rapidly reduce inflammation but increase serum VEGF level: a rationale for tumor risk during anti-HCV treatment","volume":"11","author":"Villani","year":"2016","journal-title":"PLoS ONE"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-45478\/v1","article-title":"Improvement of liver disease and inflammation in patients with advanced HCV-related cirrhosis after antiviral therapy","author":"Medrano","year":"2020","journal-title":"Res Square. [Preprint]"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.615342\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T05:07:51Z","timestamp":1612156071000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.615342\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,1]]},"references-count":51,"alternative-id":["10.3389\/fmed.2021.615342"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2021.615342","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,1]]},"article-number":"615342"}}